Effectiveness and safety of intravenous tocilizumab to treat COVID-19-associated hyperinflammatory syndrome: Covizumab-6 observational cohort.
Acute Lung Injury
/ drug therapy
Aged
Antibodies, Monoclonal, Humanized
/ therapeutic use
COVID-19
/ mortality
Cohort Studies
Cytokine Release Syndrome
/ drug therapy
Female
Ferritins
/ metabolism
Fibrin Fibrinogen Degradation Products
/ metabolism
Humans
Inflammation
/ drug therapy
Male
Middle Aged
Receptors, Interleukin-6
/ immunology
Respiratory Distress Syndrome
/ drug therapy
SARS-CoV-2
/ physiology
Survival Analysis
COVID-19 Drug Treatment
COVID-19
Cytokine release syndrome
IL-6R antagonist
SARS-CoV-2
Tocilizumab
Treatment
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
10
09
2020
revised:
04
11
2020
accepted:
09
11
2020
pubmed:
16
11
2020
medline:
29
1
2021
entrez:
15
11
2020
Statut:
ppublish
Résumé
Although the starting event in COVID-19 is a viral infection some patients present with an over-exuberant inflammatory response, leading to acute lung injury (ALI) and adult respiratory distress syndrome (ARDS). Since IL-6 plays a critical role in the inflammatory response, we assessed the efficacy and safety of tocilizumab (TCZ) in this single-centre, observational study in all Covid-19 in-patient with a proven SARS-CoV-2 rapidly progressing infection to prevent ALI and ARDS. 104 patients with COVID-19 treated with TCZ had a lower mortality rate (5·8%) compared with the regional mortality rate (11%), hospitalized patient's mortality (10%), and slightly lower than hospitalized patients treated with our standard of care alone (6%). We found that TCZ rapidly decreased acute phase reactants, ferritin and liver release of proteins. D-Dimer decreased slowly. We did not observe specific safety concerns. Early administration of IL6-R antagonists in COVID-19 patients with impending hyperinflammatory response, may be safe and effective treatment to prevent, ICU admission and further complications.
Identifiants
pubmed: 33189888
pii: S1521-6616(20)30791-9
doi: 10.1016/j.clim.2020.108631
pmc: PMC7658611
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Fibrin Fibrinogen Degradation Products
0
Receptors, Interleukin-6
0
fibrin fragment D
0
Ferritins
9007-73-2
tocilizumab
I031V2H011
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108631Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier Inc. All rights reserved.